



II. Cutaneous Melanoma

a. Screening/Diagnostic

UCI 16-82 DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study #4 (Yamamoto)

UCI 14-05 Multi-Center Evaluation of Oncogenesis via Spectral Analysis with the Melanoma Advanced Imaging Dermoscope (mAID) (Linden/Kelly)

b. Metastatic: Unresectable Not Previously Treated

i. BRAF Mutated Only

UCI 17-73
A Sequential 2-arm, Open-label Phase 1 Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors (Fruehauf)

III. Cutaneous T-Cell Lymphoma (CTCL)

b. Therapeutic

UCI 16-46

A Phase 1 Dose-Ranging Study to Investigate the Safety, Tolerability and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects with Various Lymphomas and Leukemias (Pinter-Brown)

UCI 17-36

A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma (Pinter-Brown)

UCI 17-82

A randomized, double-blind, multi-centre, placebo-controlled, parallel-arm phase 2 trial to assess safety, efficacy and pharmacokinetics of CD11301 0.03% and 0.06% gel in the treatment of Cutaneous T-Cell Lymphoma (CTCL), stages IA, IB and IIA (Pinter-Brown)

IV. Miscellaneous & Phase 1 Clinical Trials

ECOG-EAY131

Molecular Analysis for Therapy Choice (MATCH) (Bota)

UCI 16-96

A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (Zhu)

UCI 18-19

Ph Ib Study of IBI308 (PD-1 antagonist) for Advanced/ Metastatic Solid Malignancies (Zhu)

UCI 18-14

Ph I Trial of RMC-4630 (PTP SHP2) Monotherapy for Relapsed/ Refractory Solid Tumors (Ou)

SWOG S1609

(CIRB) DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)

UCI 18-21

Ph I/II LOXO-292 for RET Fusion+ Solid Tumors, Medullary Thyroid Ca & Other Tumors w/RET Activation (Ou)

UCI 18-78**

Pending
Ph I/II Study of MRTX849 in Pts w/ Adv Solid Tumors w/ KRAS G12C Mutation (Ou)